{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:51:31Z","timestamp":1790877091982,"version":"4.1.0"},"reference-count":70,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Psychosocial health services for adults with cancer should include support for cognitive symptoms and symptom clusters.<\/jats:p><\/jats:sec>Objective<\/jats:title>To characterize the frequency and severity of cognitive symptoms and to identify demographic and clinical risk factors associated with moderate to severe cognitive symptoms among outpatient adults with cancer seeking psychosocial support.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cross-sectional study analyzed data from routine patient-reported symptom screening during clinic appointments at the Princess Margaret Cancer Centre in Toronto, Canada, between January 1, 2013, and December 31, 2019. Participants were outpatient adults (aged \u226518 years) with diverse cancer diagnoses who endorsed interest in receiving psychosocial support from a health care team member. Data analysis was performed from April 2020 to June 2024.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The presence and severity of cognitive symptoms as self-rated by participants were characterized across 12 cancer types: brain or central nervous system (CNS), breast, gastrointestinal, head and neck, gynecological, thyroid, lung and bronchus, sarcoma, genitourinary, melanoma, hematological, and all other cancers. Multivariable logistic regression was used to explore the associations between demographic, clinical, and symptom factors and moderate to severe cognitive symptoms.<\/jats:p><\/jats:sec>Results<\/jats:title>Across the sample of 5078 respondents (2820 females [55.5%]; mean [SD] age at time of survey, 56.0 [14.1] years) requesting psychosocial support, 3480 (68.5%) reported cognitive symptoms of any severity, ranging from 59.5% in sarcoma to 86.5% in brain or CNS cancer. Moderate to severe cognitive symptoms were reported by 1544 patients (30.4%), with the proportions being 51.3% for patients with brain or CNS, 37.0% for breast, 36.2% for thyroid, 30.9% for melanoma, 29.6% for head and neck, 28.3% for gastrointestinal, 28.2% for hematological, 28.1% for gynecological, 24.9% for lung and bronchus, 24.9% for sarcoma, 21.0% for genitourinary, and 26.8% for all other cancers. Across the entire sample, moderate to severe cognitive symptoms were associated with recurrence or progression involving the CNS (odds ratio [OR], 2.62; 95% CI, 1.80-3.81), depression (OR, 1.92; 95% CI, 1.59-2.31), tiredness (OR, 1.82; 95% CI, 1.52-2.19), drowsiness (OR, 1.64; 95% CI, 1.39-1.93), anxiety (OR, 1.57; 95% CI, 1.30-1.89), shortness of breath (OR, 1.38; 95% CI, 1.16-1.61), female sex (OR, 1.33; 95% CI, 1.14-1.56), first-line chemotherapy received (OR, 1.22; 95% CI, 1.05-1.41), and metastatic disease at diagnosis (OR, 0.74; 95% CI, 0.61-0.89). Within individual cancer types, tiredness and depression were consistently associated with moderate to severe cognitive symptoms.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This cross-sectional study found that cognitive symptoms were frequently reported by patients across a wide range of cancer types; higher severity of cognitive symptoms was consistently associated with higher symptom burden. The findings could be used to inform decision-making regarding access to cognitive screening, assessment, and supportive care in outpatient oncology clinics.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.30833","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T15:34:32Z","timestamp":1724859272000},"page":"e2430833","source":"Crossref","is-referenced-by-count":34,"title":["Cognitive Symptoms Across Diverse Cancers"],"prefix":"10.1001","volume":"7","author":[{"given":"Samantha J.","family":"Mayo","sequence":"first","affiliation":[{"name":"Lawrence Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Supportive Care, Princess Margaret Cancer Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Edelstein","sequence":"additional","affiliation":[{"name":"Department of Supportive Care, Princess Margaret Cancer Centre, Toronto, Ontario, Canada"},{"name":"Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eshetu G.","family":"Atenafu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rand","family":"Ajaj","sequence":"additional","affiliation":[{"name":"Lawrence Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Supportive Care, Princess Margaret Cancer Centre, Toronto, Ontario, Canada"},{"name":"Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori J.","family":"Bernstein","sequence":"additional","affiliation":[{"name":"Department of Supportive Care, Princess Margaret Cancer Centre, Toronto, Ontario, Canada"},{"name":"Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"issue":"4","key":"zoi240926r1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11764-009-0098-x","article-title":"Confronting chemobrain: an in-depth look at survivors\u2019 reports of impact on work, social networks, and health care response.","volume":"3","author":"Boykoff","year":"2009","journal-title":"J Cancer Surviv"},{"issue":"2","key":"zoi240926r2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ejon.2012.06.002","article-title":"Impact of perceived cognitive impairment in breast cancer survivors.","volume":"17","author":"Von Ah","year":"2013","journal-title":"Eur J Oncol Nurs"},{"issue":"1","key":"zoi240926r3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3109\/09540261.2013.864260","article-title":"Prevalence, mechanisms, and management of cancer-related cognitive impairment.","volume":"26","author":"Janelsins","year":"2014","journal-title":"Int Rev Psychiatry"},{"issue":"3","key":"zoi240926r4","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1053\/j.seminoncol.2011.03.014","article-title":"An update on cancer- and chemotherapy-related cognitive dysfunction: current status.","volume":"38","author":"Janelsins","year":"2011","journal-title":"Semin Oncol"},{"issue":"1","key":"zoi240926r5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.semradonc.2017.08.008","article-title":"Head and neck cancer survivorship: learning the needs, meeting the needs.","volume":"28","author":"Ringash","year":"2018","journal-title":"Semin Radiat Oncol"},{"key":"zoi240926r6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s13104-015-1188-7","article-title":"What do haematological cancer survivors want help with? a cross-sectional investigation of unmet supportive care needs.","volume":"8","author":"Hall","year":"2015","journal-title":"BMC Res Notes"},{"issue":"6","key":"zoi240926r7","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.jpainsymman.2015.06.019","article-title":"Impact of cancer and its treatments on cognitive function: advances in research from the Paris International Cognition and Cancer Task Force symposium and update since 2012.","volume":"50","author":"Joly","year":"2015","journal-title":"J Pain Symptom Manage"},{"key":"zoi240926r8","doi-asserted-by":"crossref","DOI":"10.1007\/s00520-020-05860-9","article-title":"Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group.","author":"Mayo","year":"2021","journal-title":"Support Care Cancer"},{"key":"zoi240926r9","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.893264","article-title":"The cognitive effects of radiotherapy for brain metastases.","volume":"12","author":"Lehrer","year":"2022","journal-title":"Front Oncol"},{"issue":"8","key":"zoi240926r10","article-title":"Long-term neurocognitive and other side effects of radiotherapy, with or without chemotherapy, for glioma.","volume":"8","author":"Lawrie","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"zoi240926r11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ctrv.2012.11.001","article-title":"A meta-analysis of the effects of chemotherapy on cognition in patients with cancer.","volume":"39","author":"Hodgson","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"zoi240926r12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.neubiorev.2017.10.028","article-title":"Cognitive impairment in breast cancer survivors treated with chemotherapy depends on control group type and cognitive domains assessed: a multilevel meta-analysis.","volume":"83","author":"Bernstein","year":"2017","journal-title":"Neurosci Biobehav Rev"},{"issue":"2","key":"zoi240926r13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jamaoncol.2015.4333","article-title":"Neurotoxic effects of anthracycline- vs nonanthracycline-based chemotherapy on cognition in breast cancer survivors.","volume":"2","author":"Kesler","year":"2016","journal-title":"JAMA Oncol"},{"key":"zoi240926r14","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.radonc.2018.09.012","article-title":"A cross sectional study in cognitive and neurobehavioral impairment in long-term nasopharyngeal cancer survivors treated with intensity-modulated radiotherapy.","volume":"131","author":"McDowell","year":"2019","journal-title":"Radiother Oncol"},{"issue":"6","key":"zoi240926r15","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/bjh.14211","article-title":"What is known and unknown about chemotherapy-related cognitive impairment in patients with haematological malignancies and areas of needed research.","volume":"174","author":"Williams","year":"2016","journal-title":"Br J Haematol"},{"issue":"10","key":"zoi240926r16","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/bmt.2013.61","article-title":"A systematic review and meta-analysis of changes in cognitive functioning in adults undergoing hematopoietic cell transplantation.","volume":"48","author":"Phillips","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"zoi240926r17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/ecc.12642","article-title":"Cognitive impairment among prostate cancer patients: an overview of reviews.","volume":"26","author":"Treanor","year":"2017","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"2","key":"zoi240926r18","first-page":"135","article-title":"The multifactorial model of cancer-related cognitive impairment.","volume":"50","author":"Oppegaard","year":"2023","journal-title":"Oncol Nurs Forum"},{"issue":"7","key":"zoi240926r19","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S1470-2045(10)70294-1","article-title":"International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer.","volume":"12","author":"Wefel","year":"2011","journal-title":"Lancet Oncol"},{"issue":"4","key":"zoi240926r20","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1017\/S1355617714000149","article-title":"Cognitive dysfunction after chemotherapy for breast cancer.","volume":"20","author":"Edelstein","year":"2014","journal-title":"J Int Neuropsychol Soc"},{"issue":"2","key":"zoi240926r21","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s11764-015-0476-5","article-title":"Prevalence of perceived cognitive dysfunction in survivors of a wide range of cancers: results from the 2010 LIVESTRONG survey.","volume":"10","author":"Schmidt","year":"2016","journal-title":"J Cancer Surviv"},{"key":"zoi240926r22","doi-asserted-by":"crossref","DOI":"10.1007\/s11764-021-01023-9","article-title":"Self-perceived cognitive functioning and quality of life among cancer survivors: results from the PROFILES registry.","author":"Oerlemans","year":"2022","journal-title":"J Cancer Surviv"},{"issue":"20","key":"zoi240926r23","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"9596","key":"zoi240926r24","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"zoi240926r25","doi-asserted-by":"crossref","first-page":"e513","DOI":"10.1200\/JOP.2015.010066","article-title":"Easier said than done: keys to successful implementation of the Distress Assessment and Response Tool (DART) program.","volume":"12","author":"Li","year":"2016","journal-title":"J Oncol Pract"},{"issue":"2","key":"zoi240926r26","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s11136-004-5332-4","article-title":"Development and evaluation of an instrument to assess social difficulties in routine oncology practice.","volume":"14","author":"Wright","year":"2005","journal-title":"Qual Life Res"},{"issue":"1","key":"zoi240926r27","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/pon.1705","article-title":"The Social Difficulties Inventory (SDI): development of subscales and scoring guidance for staff.","volume":"20","author":"Wright","year":"2011","journal-title":"Psychooncology"},{"issue":"10","key":"zoi240926r28","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/pon.3522","article-title":"Self-reported cognitive concerns and abilities: two sides of one coin?","volume":"23","author":"Lai","year":"2014","journal-title":"Psychooncology"},{"issue":"5","key":"zoi240926r29","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"zoi240926r30","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1007\/s11136-013-0387-8","article-title":"Using the EORTC-QLQ-C30 in clinical practice for patient management: identifying scores requiring a clinician\u2019s attention.","volume":"22","author":"Snyder","year":"2013","journal-title":"Qual Life Res"},{"issue":"12","key":"zoi240926r31","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1007\/s11136-019-02261-2","article-title":"Establishing clinically-relevant terms and severity thresholds for Patient-Reported Outcomes Measurement Information System\u00ae (PROMIS\u00ae) measures of physical function, cognitive function, and sleep disturbance in people with cancer using standard setting.","volume":"28","author":"Rothrock","year":"2019","journal-title":"Qual Life Res"},{"issue":"2","key":"zoi240926r32","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jpainsymman.2010.04.020","article-title":"A multicenter study comparing two numerical versions of the Edmonton Symptom Assessment System in palliative care patients.","volume":"41","author":"Watanabe","year":"2011","journal-title":"J Pain Symptom Manage"},{"issue":"3","key":"zoi240926r33","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jpainsymman.2016.10.370","article-title":"The Edmonton Symptom Assessment System 25 years later: past, present, and future developments.","volume":"53","author":"Hui","year":"2017","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"zoi240926r35","first-page":"71","article-title":"Association of neurocognitive deficits with radiotherapy or chemoradiotherapy for patients with head and neck cancer.","volume":"144","author":"Zer","year":"2018","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"1","key":"zoi240926r36","first-page":"89","article-title":"Neurocognitive impairment, neurobehavioral symptoms, fatigue, sleep disturbance, and depressive symptoms in patients with newly diagnosed glioblastoma.","volume":"10","author":"Sekely","year":"2022","journal-title":"Neurooncol Pract"},{"issue":"6","key":"zoi240926r37","article-title":"Neurocognitive performance in adults treated with radiation for a primary brain tumor.","volume":"7","author":"Tsang","year":"2022","journal-title":"Adv Radiat Oncol"},{"issue":"11","key":"zoi240926r38","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1159\/000518848","article-title":"The impact of stereotactic or whole brain radiotherapy on neurocognitive functioning in adult patients with brain metastases: a systematic review and meta-analysis.","volume":"44","author":"van Grinsven","year":"2021","journal-title":"Oncol Res Treat"},{"issue":"5","key":"zoi240926r39","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.clon.2021.01.003","article-title":"Group and individual change in cognitive functioning in patients with 1 to 10 brain metastases following gamma knife radiosurgery.","volume":"33","author":"Schimmel","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"4","key":"zoi240926r40","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.adro.2019.07.006","article-title":"Pretreatment volume of MRI-determined white matter injury predicts neurocognitive decline after hippocampal avoidant whole-brain radiation therapy for brain metastases: secondary analysis of NRG Oncology Radiation Therapy Oncology Group 0933.","volume":"4","author":"Bovi","year":"2019","journal-title":"Adv Radiat Oncol"},{"issue":"4","key":"zoi240926r41","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jama.2016.9839","article-title":"Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial.","volume":"316","author":"Brown","year":"2016","journal-title":"JAMA"},{"issue":"8","key":"zoi240926r42","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1470-2045(17)30441-2","article-title":"Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC\u00b73): a multicentre, randomised, controlled, phase 3 trial.","volume":"18","author":"Brown","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10","key":"zoi240926r43","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1200\/JCO.19.02767","article-title":"Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase III trial NRG Oncology CC001.","volume":"38","author":"Brown","year":"2020","journal-title":"J Clin Oncol"},{"key":"zoi240926r44","doi-asserted-by":"crossref","first-page":"vi137","DOI":"10.1093\/neuonc\/nox168.562","article-title":"NCOG-01: patient-reported cognitive concerns and quality of life in brain metastases.","volume":"19","author":"Richard","year":"2017","journal-title":"Neuro Oncol"},{"key":"zoi240926r45","doi-asserted-by":"crossref","DOI":"10.1007\/s11764-024-01573-8","article-title":"Survivorship concerns among individuals diagnosed with metastatic cancer: findings from the Cancer Experience Registry.","author":"Brick","year":"2024","journal-title":"J Cancer Surviv"},{"key":"zoi240926r46","doi-asserted-by":"crossref","DOI":"10.1007\/s11764-023-01417-x","article-title":"Application of a revised model for coping with advanced cancer to qualitatively explore lung cancer survivors\u2019 experiences of ongoing physical effects, novel treatments, uncertainty, and coping.","author":"Laidsaar-Powell","year":"2023","journal-title":"J Cancer Surviv"},{"issue":"4","key":"zoi240926r47","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s11764-018-0692-x","article-title":"Systematic review of self-reported cognitive function in cancer patients following chemotherapy treatment.","volume":"12","author":"Bray","year":"2018","journal-title":"J Cancer Surviv"},{"issue":"5","key":"zoi240926r48","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1002\/cam4.2069","article-title":"Cognitive complaints in cancer survivors and expectations for support: results from a web-based survey.","volume":"8","author":"Lange","year":"2019","journal-title":"Cancer Med"},{"issue":"12","key":"zoi240926r49","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/pon.4351","article-title":"Intraindividual variability in reaction time before and after neoadjuvant chemotherapy in women diagnosed with breast cancer.","volume":"26","author":"Yao","year":"2017","journal-title":"Psychooncology"},{"issue":"9","key":"zoi240926r50","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/hed.25198","article-title":"Pretreatment neurocognitive function and self-reported symptoms in patients with newly diagnosed head and neck cancer compared with noncancer cohort.","volume":"40","author":"Bernstein","year":"2018","journal-title":"Head Neck"},{"issue":"3","key":"zoi240926r51","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/pon.4571","article-title":"Cognition, quality-of-life, and symptom clusters in breast cancer: using bayesian networks to elucidate complex relationships.","volume":"27","author":"Xu","year":"2018","journal-title":"Psychooncology"},{"issue":"11","key":"zoi240926r52","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nrc2507","article-title":"Cytokines and their relationship to the symptoms and outcome of cancer.","volume":"8","author":"Seruga","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"zoi240926r53","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1037\/0033-2909.90.2.218","article-title":"Ubiquitous halo.","volume":"90(2)","author":"Cooper","year":"1981","journal-title":"Psychol Bull"},{"issue":"6","key":"zoi240926r54","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1188\/11.CJON.607-615","article-title":"Putting evidence into practice: evidence-based interventions for cancer and cancer treatment-related cognitive impairment.","volume":"15","author":"Von Ah","year":"2011","journal-title":"Clin J Oncol Nurs"},{"issue":"12","key":"zoi240926r55","first-page":"591","article-title":"Mechanisms and treatment for cancer- and chemotherapy-related cognitive impairment in survivors of non-CNS malignancies.","volume":"32","author":"Chung","year":"2018","journal-title":"Oncology (Williston Park)"},{"key":"zoi240926r56","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.neubiorev.2020.07.002","article-title":"The microbiota-gut-brain axis: an emerging therapeutic target in chemotherapy-induced cognitive impairment.","volume":"116","author":"Subramaniam","year":"2020","journal-title":"Neurosci Biobehav Rev"},{"issue":"6","key":"zoi240926r57","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/CCO.0000000000000578","article-title":"Emerging mechanistic underpinnings and therapeutic targets for chemotherapy-related cognitive impairment.","volume":"31","author":"Gibson","year":"2019","journal-title":"Curr Opin Oncol"},{"issue":"5","key":"zoi240926r58","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1017\/S1355617716000126","article-title":"Pretreatment differences in intraindividual variability in reaction time between women diagnosed with breast cancer and healthy controls.","volume":"22","author":"Yao","year":"2016","journal-title":"J Int Neuropsychol Soc"},{"issue":"6","key":"zoi240926r59","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.euf.2016.04.009","article-title":"Prospective evaluation of the impact of antiangiogenic treatment on cognitive functions in metastatic renal cancer.","volume":"2","author":"Joly","year":"2016","journal-title":"Eur Urol Focus"},{"issue":"1","key":"zoi240926r60","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbmt.2019.09.037","article-title":"Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy.","volume":"26","author":"Ruark","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"zoi240926r61","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1007\/s00520-019-05168-3","article-title":"Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study.","volume":"28","author":"Rogiers","year":"2020","journal-title":"Support Care Cancer"},{"issue":"5","key":"zoi240926r62","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/pon.5623","article-title":"Prevalence of cognitive impairment and change in patients with breast cancer: a systematic review of longitudinal studies.","volume":"30","author":"Dijkshoorn","year":"2021","journal-title":"Psychooncology"},{"issue":"1","key":"zoi240926r63","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13293-022-00425-3","article-title":"Overall and sex-specific risk factors for subjective cognitive decline: findings from the 2015-2018 Behavioral Risk Factor Surveillance System Survey.","volume":"13","author":"Schliep","year":"2022","journal-title":"Biol Sex Differ"},{"issue":"13","key":"zoi240926r64","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.21.02377","article-title":"Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials.","volume":"40","author":"Unger","year":"2022","journal-title":"J Clin Oncol"},{"key":"zoi240926r65","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000837","article-title":"Sex-specific and gender-specific aspects in patient-reported outcomes.","volume":"5","author":"Hertler","year":"2020","journal-title":"ESMO Open"},{"issue":"5","key":"zoi240926r66","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1188\/08.CJON.725-729","article-title":"Oncology nurses\u2019 awareness of cognitive impairment secondary to chemotherapy.","volume":"12","author":"Myers","year":"2008","journal-title":"Clin J Oncol Nurs"},{"issue":"9","key":"zoi240926r67","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1007\/s00520-019-04866-2","article-title":"Cognitive rehabilitation for cancer-related cognitive dysfunction: a systematic review.","volume":"27","author":"Fernandes","year":"2019","journal-title":"Support Care Cancer"},{"issue":"2","key":"zoi240926r68","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/pon.1878","article-title":"Development of CBT for chemotherapy-related cognitive change: results of a waitlist control trial.","volume":"21","author":"Ferguson","year":"2012","journal-title":"Psychooncology"},{"issue":"8","key":"zoi240926r69","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1007\/s00520-018-4135-z","article-title":"A brief psychoeducational intervention improves memory contentment in breast cancer survivors with cognitive concerns: results of a single-arm prospective study.","volume":"26","author":"Bernstein","year":"2018","journal-title":"Support Care Cancer"},{"issue":"3","key":"zoi240926r70","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s11060-019-03130-1","article-title":"Cognitive rehabilitation for executive dysfunction in brain tumor patients: a pilot randomized controlled trial.","volume":"142","author":"Richard","year":"2019","journal-title":"J Neurooncol"},{"key":"zoi240926r34","volume-title":"International Classification of Diseases for Oncology (?ICD-O)","author":"World Health Organization","year":"2013","edition":"3rd ed, 1st rev"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2822904\/mayo_2024_oi_240926_1724265053.14142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T15:35:16Z","timestamp":1724859316000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2822904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,28]]},"references-count":70,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.30833","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,28]]}}}